The mood stabilizer valproate activates human FGF 1 gene promoter through inhibiting HDAC and GSK‐3 activities
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Valproic acid (VPA) is the primary mood‐stabilizing drug to exert neuroprotective effects and to treat bipolar disorder in clinic. Fibroblast growth factor 1 (FGF1) has been shown to regulate cell proliferation, cell division, and neurogenesis. Human FGF1 gene 1B promoter (−540 to +31)‐driven green fluorescence (F1BGFP) has been shown to recapitulate endogenous FGF1 gene expression and facilitates the isolation of neural stem/progenitor cells (NSPCs) from developing and adult mouse brains. In this study, we provide several lines of evidence to demonstrate the underlying mechanisms of VPA in activating FGF‐1B promoter activity: (i) VPA significantly increased the FGF‐1B mRNA expression and the percentage of F1BGFP(+) cells; (ii) the increase of F1BGFP expression by VPA involves changes of regulatory factor X (RFX) 1‐3 transcriptional complexes and the increase of histone H3 acetylation on the 18‐bp cis‐element of FGF‐1B promoter; (iii) treatments of other histone deacetylases (HDAC) inhibitors, sodium butyrate and trichostatin A, significantly increased the expression levels of FGF‐1B, RFX2, and RFX3 transcripts; (iv) treatments of glycogen synthase kinase 3 (GSK‐3) inhibitor, lithium, or GSK‐3 siRNAs also significantly activated FGF‐1B promoter; (v) VPA specifically enhanced neuronal differentiation in F1BGFP(+) embryonic stem cells and NSPCs rather than GFP(−) cells. This study suggested, for the first time, that VPA activates human FGF1 gene promoter through inhibiting HDAC and GSK‐3 activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945 · cited 1×
“Fibroblast growth factors (FGF) play important roles in many cellular processes, such as cell growth, cell differentiation, and neurogenesis (Beenken and Mohammadi 2009).”
BackgroundPhiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321 · cited 2×
“2004), while LiCl is the inhibitor of GSK-3 (Stambolic et al. 1996; Zhang et al. 2003).”
BackgroundRecovery of learning and memory is associated with chromatin remodelling
Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L.-H. (2007) · Nature · doi:10.1038/nature05772 · Cited by 1,227 · cited 1×
“The role of HDACs in regulating the function and development of nervous system has been studied in several animal models (Fischer et al. 2007; Ma et al. 2010).”
BackgroundMultiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676
Dysregulation of the fibroblast growth factor system in major depression
Evans, S. J., Choudary, P. V., Neal, C. R., Li, J. Z., Vawter, M. P., Tomita, H., Lopez, J. F., Thompson, R. C., Meng, F., Stead, J. D., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406788101 · Cited by 424 · cited 1×
“The dysregulation of FGF1 has been linked to major depressive disorders (Evans et al. 2004).”
BackgroundYasuda, S., Liang, M.-H., Marinova, Z., Yahyavi, A., & Chuang, D.-M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002099 · Cited by 358 · cited 3×
“Recent studies also demonstrate that VPA or LiCl treatment increases the expression of brain-derived neurotrophic factor (BDNF) (Yasuda et al. 2007).”
BackgroundPolter, A., Beurel, E., Yang, S., Garner, R., Song, L., Miller, C. A., Sweatt, J. D., McMahon, L., Bartolucci, A. A., Li, X., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.43 · Cited by 225 · cited 1×
“FGF-1B promoter is regulated by GSK-3 activities Recent studies have suggested that GSK-3 is a potential target for mood-disorder therapy (Wada 2009; Polter et al. 2010).”
BackgroundThe Fibroblast Growth Factor Family: Neuromodulation of Affective Behavior
Turner, C. A., Watson, S. J., & Akil, H. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.037 · Cited by 160
Antidepressant-like effects of intracerebroventricular FGF2 in rats
Turner, C. A., Gula, E. L., Taylor, L. P., Watson, S. J., & Akil, H. (2008) · Brain Research · doi:10.1016/j.brainres.2008.05.088 · Cited by 125
Cited by
Shukla, S., & Tekwani, B. L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00537 · Cited by 314
Rizzo, L. B., Costa, L. G., Mansur, R. B., Swardfager, W., Belangero, S. I., Grassi-Oliveira, R., McIntyre, R. S., Bauer, M. E., & Brietzke, E. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.004 · Cited by 183
Sabers, A., Bertelsen, F. C. B., Scheel-Krüger, J., Nyengaard, J. R., & Møller, A. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.07.036 · Cited by 43
Metadata
- Authors
- Kao, C., Hsu, Y., Liu, J., Lee, D., Chung, Y., & Chiu, I.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2013-05-21
- Volume
- 126
- Issue
- 1
- Pages
- 4-18
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1966959753
- Cited by
- 37
- References
- 10
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.